Phase I Dose Escalation Study of ON 01910.Na by 3-day Continuous Infusion in Patients With Advanced Cancer

Trial Profile

Phase I Dose Escalation Study of ON 01910.Na by 3-day Continuous Infusion in Patients With Advanced Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Rigosertib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Onconova Therapeutics
  • Most Recent Events

    • 20 Feb 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.
    • 20 Feb 2012 Actual initiation date (August 2006) and actual patient no 29 added as reported by ClinicalTrials.gov.
    • 20 Feb 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top